Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radavirsen
- Development stage
- Discontinued
- Lead developer
- Sarepta Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Radavirsen is a phosphorodiamidate morpholino oligomer (PMOplus®) developed by Sarepta Therapeutics, Inc. and the National Institute of Allergy and Infectious Diseases. It is an RNA-targeted therapeutic candidate designed for the treatment of influenza A virus infections. Its mechanism of action involves recognizing and binding to specific mRNA sequences in the matrix segment of influenza A, thereby physically blocking the translation and processing of M1 and M2 transcripts, which are crucial for viral replication. The drug was in Phase I clinical trials for influenza A virus infections but has since been discontinued.
- Other names
- radavirsen
02
Targets
CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on Radavirsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radavirsen.